Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

Item

http://www.wikidata.org/entity/Q38418171

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

@en

type

Item

label

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

@en

prefLabel

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

@en

P1476

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

@en

P2093

Attilio Orazi

http://www.w3.org/2001/XMLSchema#string

Crystal Miller

http://www.w3.org/2001/XMLSchema#string

David Leibowitz

http://www.w3.org/2001/XMLSchema#string

Elizabeth O Hexner

http://www.w3.org/2001/XMLSchema#string

Ellen K Ritchie

http://www.w3.org/2001/XMLSchema#string

Erin P Demakos

http://www.w3.org/2001/XMLSchema#string

Gail J Roboz

http://www.w3.org/2001/XMLSchema#string

Heike L Pahl

http://www.w3.org/2001/XMLSchema#string

James Siuty

http://www.w3.org/2001/XMLSchema#string

Jill Kleczko

http://www.w3.org/2001/XMLSchema#string

P2860

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

P304

2543-2551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2014.1001986

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Judith D Goldberg

Grace R Jeschke

P577

2015-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25563429

http://www.w3.org/2001/XMLSchema#string

P932

5665563

http://www.w3.org/2001/XMLSchema#string